Announcement Regarding Tianxin Pharmaceutical Obtaining Folic Acid CEP Certificate

Recently, Tianxin Pharmaceutical announced the good news that it has successfully obtained the Folic Acid CEP Certificate (Certificate No.: CEP2022-378-Rev 00) issued by the European Medicines Agency for the Quality of Medicines (EDQM). This achievement marks a significant breakthrough for Tianxin Pharmaceutical in folic acid product quality control and international market access, further enhancing the company's competitiveness in the global pharmaceutical field.

The CEP certificate, or European Pharmacopoeia Suitability Certificate, is highly authoritative and influential in the international pharmaceutical industry. Obtaining this certificate means that Tianxin Pharmaceutical's folic acid products meet the stringent requirements of the European Pharmacopoeia and can be freely sold in the EU and EEA markets. This not only reflects Tianxin Pharmaceutical's outstanding strength in production processes and quality control but also indicates a solid step forward in its international development.

This acquisition of the folic acid CEP certificate is the result of Tianxin Pharmaceutical's years of focus on research and development innovation and rigorous quality control. In the future, Tianxin Pharmaceutical will seize this opportunity to further expand into the international market, increase investment in research and development, continuously improve product quality and service levels, and make greater contributions to the global pharmaceutical and healthcare industry.